No effect of single dose ofloxacin on postoperative infection rate after first-trimester abortion. A clinical, controlled trial.
In a double-blind stratificated, placebo controlled study the efficacy and safety of a single oral dose of ofloxanin (Tarivid) (400 mg) in preventing postabortal pelvic inflammatory disease (P-PID) in women with induced first-trimester abortions were assessed. The tablets were given 1 1/2-2 h before the abortion, and the women were followed one month after the operation. Group I consisted of 308 with previous PID. Ofloxacin tablets were given to 149 women and 159 women received placebo tablets. In the ofloxacin group 20 women (13.4%) and in the placebo group 27 women (17%) developed P-PID, a non-significant difference (p = 0.39). Group II consisted of 765 women without a history of PID. Ofloxacin tablets were given to 376 women and 389 women received placebo tablets. Thirty-five women (9.3%) in the ofloxacin group and 46 women (11.9%) in the placebo group developed P-PID, a non-significant difference (p = 0.26). A single oral dose of ofloxacin (400 mg) did not reduce the incidence of P-PID either among women with previous PID or among women without previous PID.
Nielsen
I K
IK
Department of Obstetrics and Gynecology, Glostrup University Hospital, Denmark.
Engdahl
E
E
Larsen
T
T
D000028:Abortion, Induced / Q000009:adverse effects*; D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015242:Ofloxacin / Q000008:administration & dosage / Q000627:therapeutic use*; D000292:Pelvic Inflammatory Disease / Q000209:etiology / Q000517:prevention & control*; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011292:Premedication; D011446:Prospective Studies
D015242:Ofloxacin